Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 07:55:55 2024-07-01 EDT			5-day change	1st Jan Change
80 ^SEK	-0.50%		+2.17%	+100.00%

05-23	Xspray Pharma AB Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib	CI
05-20	Xspray Pharma AB Appoints Linda Glimberg as Chief Operating Officer, Effective June 1, 2024	CI

Xspray Pharma AB Appoints Anna-Karin as Global Head of Marketing and Sales, Effective March 15, 2022

February 07, 2022 at 02:55 am

Xspray Pharma AB (publ) announced that the company has hired Anna-Karin Ekberg as Global Head of Marketing and Sales. She will take office in mid-March 2022. Anna-Karin comes most recently from her position as Global Marketing Director at Oncopeptides AB.

Anna-Karin will take office on March 15, 2022 and will become part of the company's management group.

Latest news about Xspray Pharma AB

Xspray Pharma AB Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib	05-23	CI
Xspray Pharma AB Appoints Linda Glimberg as Chief Operating Officer, Effective June 1, 2024	05-20	CI
Xspray Pharma AB Appoints Niklas Adenborg as Chief Financial Officer, Effective July 1, 2024	05-20	CI
Xspray Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Xspray Pharma Announces Fourth Product Candidate, Targeting USD 2.3 Billion Market	04-22	CI
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-14	CI
US FDA Accepts Xspray Pharma's Refiled Application for Potential Leukemia Treatment	02-12	MT
FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA	02-12	CI
Xspray Pharma AB Appoints Kerstin Hasselgren as Head of IR	02-07	CI
Xspray Pharma AB Announces CFO Changes	02-07	CI
Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage	11-21	CI
Xspray Pharma AB Through HyNap? technology Announces Results from Drug Interaction Studies	11-08	CI
Xspray Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Xspray Pharma AB Announces Nomination Committee for the Annual General Meeting 2024	23-10-24	CI
Certain Shares of Xspray Pharma AB are subject to a Lock-Up Agreement Ending on 25-SEP-2023.	23-09-24	CI
Xspray Pharma Names Chief Commercial Officer	23-09-15	MT
Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer	23-09-15	CI
Xspray Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
US FDA Requests More Data from Xspray Pharma for Dasynoc Drug Candidate; Shares Fall 7%	23-07-11	MT
Xspray Pharma AB Receives Request for Additional Information Concerning Dasynoc from FDA	23-07-11	CI
Xspray Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Xspray Pharma AB Auditor Raises 'Going Concern' Doubt	23-03-28	CI
Xspray Pharma AB Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc for the Treatment of Chronic Myeloid Leukemia and Acute Lymphatic Leukemia	23-02-23	CI
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-15	CI
Xspray Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-15	CI

Chart Xspray Pharma AB

Duration

Period

More charts

Company Profile

XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

80.4 SEK

Average target price

107 SEK

Spread / Average Target

+33.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
XSPRAY PHARMA AB	+100.00%	256M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+17.00%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.84%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs